Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Fadnes, Bodil ^a   Uhlin Hansen, Lars ^a,b   Lindin, Inger ^a,c   Rekdal, Øystein ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c LYTIX BIOPHARMA AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHONDROITIN SULFATE; HEPARAN SULFATE; LACTOFERRICIN; LTX 302; LTX 315; LTX 318; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; LACTOFERRICIN B; LACTOFERRIN; PEPTIDE FRAGMENT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL SURFACE; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ERYTHROCYTE; HUMAN; HUMAN CELL; NONHUMAN; ANIMAL; APOPTOSIS; CATTLE; CELL LINE; CHEMISTRY; DRUG EFFECT; HEMOLYSIS; IMMUNOLOGY; NEOPLASM; PATHOLOGY; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; CATTLE; CELL LINE; CHONDROITIN SULFATES; ERYTHROCYTES; HEMOLYSIS; HEPARITIN SULFATE; LACTOFERRIN; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953177039     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-116     Document Type: Article

References (69)

1. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 2000, 15(2):151-160.
2. Cruciani RA, Barker JL, Durell SR, Raghunathan G, Guy HR, Zasloff M, Stanley EF. Magainin 2, a natural antibiotic from frog skin, forms ion channels in lipid bilayer membranes. Eur J Pharmacol 1992, 226(4):287-296. 10.1016/0922-4106(92)90045-W, 1383011.
3. Ohsaki Y, Gazdar AF, Chen HC, Johnson BE. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 1992, 52(13):3534-3538.
4. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 2003, 24(7):945-953. 10.1016/S0196-9781(03)00194-3, 14499271.
5. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003, 55(1):27-55. 10.1124/pr.55.1.2, 12615953.
6. Dennison SR, Whittaker M, Harris F, Phoenix DA. Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci 2006, 7(6):487-499. 10.2174/138920306779025611, 17168782.
7. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006, 15(8):933-946. 10.1517/13543784.15.8.933, 16859395.
8. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002, 22(5):2703-2710.
9. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Lokke C, Ponthan F, Johnsen JI, Sveinbjornsson B, Kogner P, et al. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 2006, 119(3):493-500. 10.1002/ijc.21886, 16572423.
10. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003, 278(23):21018-21023. 10.1074/jbc.M211204200, 12646578.
11. Papo N, Seger D, Makovitzki A, Kalchenko V, Eshhar Z, Degani H, Shai Y. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 2006, 66(10):5371-5378. 10.1158/0008-5472.CAN-05-4569, 16707464.
12. Makovitzki A, Fink A, Shai Y. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res 2009, 69(8):3458-3463. 10.1158/0008-5472.CAN-08-3021, 19351852.
13. Papo N, Braunstein A, Eshhar Z, Shai Y. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 2004, 64(16):5779-5786. 10.1158/0008-5472.CAN-04-1438, 15313920.
14. Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjornsson B, Rekdal O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother 2010, 59(8):1285-1294. 10.1007/s00262-010-0857-6, 20422410.
15. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991, 51(1):3062-3066.
16. Bucana CD, Hoyer LC, Schroit AJ, Kleinerman E, Fidler IJ. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am J Pathol 1983, 112(1):101-111. 1916313, 6859224.
17. Sugimura M, Donato R, Kakkar VV, Scully MF. Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagul Fibrinolysis 1994, 5(3):365-373.
18. Rao LV, Tait JF, Hoang AD. Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. Thromb Res 1992, 67(5):517-531. 10.1016/0049-3848(92)90013-Z, 1448786.
19. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997, 14(5):569-576. 10.1023/A:1018580324971, 9298689.
20. Dube DH, Bertozzi CR. Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005, 4(6):477-488. 10.1038/nrd1751, 15931257.
21. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998, 102(9):1662-1673. 10.1172/JCI4105, 509114, 9802880.
22. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 2001, 61(14):5562-5569.
23. Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008, 21(7):817-825. 10.1038/modpathol.2008.37, 18469798.
24. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004, 10(19):6612-6621. 10.1158/1078-0432.CCR-04-0348, 15475451.
25. Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002, 19(3):312-331. 10.1039/b100916h, 12137280.
26. Sugahara K, Mikami T, Uyama T, Mizuguchi S, Nomura K, Kitagawa H. Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr Opin Struct Biol 2003, 13(5):612-620. 10.1016/j.sbi.2003.09.011, 14568617.
27. Tumova S, Woods A, Couchman JR. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000, 32(3):269-288. 10.1016/S1357-2725(99)00116-8, 10716625.
28. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008, 9(5):224. 10.1186/gb-2008-9-5-224, 2441458, 18505598.
29. Fadnes B, Rekdal T, Uhlin-Hansen L. The anticancer activity of lytic peptides is inhibited by heparan sulfate on the cell surface of tumor cells. BMC Cancer 2009, 9(183). 2703650, 19527490.
30. Schmidtchen A, Frick IM, Bjorck L. Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin. Mol Microbiol 2001, 39(3):708-713. 10.1046/j.1365-2958.2001.02251.x, 11169110.
31. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 2002, 46(1):157-168. 10.1046/j.1365-2958.2002.03146.x, 12366839.
32. James S, Gibbs BF, Toney K, Bennett HP. Purification of antimicrobial peptides from an extract of the skin of Xenopus laevis using heparin-affinity HPLC: characterization by ion-spray mass spectrometry. Anal Biochem 1994, 217(1):84-90. 10.1006/abio.1994.1086, 8203742.
33. Yang N, Stensen W, Svendsen JS, Rekdal O. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res 2002, 60(4):187-197. 10.1034/j.1399-3011.2002.21008.x, 12366526.
34. Eliassen LT, Haug BE, Berge G, Rekdal O. Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications. J Pept Sci 2003, 9(8):510-517. 10.1002/psc.472, 12952392.
35. Yang N, Lejon T, Rekdal O. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci 2003, 9(5):300-311. 10.1002/psc.457, 12803496.
36. Yang N, Strom MB, Mekonnen SM, Svendsen JS, Rekdal O. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci 2004, 10(1):37-46. 10.1002/psc.470, 14959890.
37. Esko JD, Stewart TE, Taylor WH. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA 1985, 82(10):3197-3201. 10.1073/pnas.82.10.3197, 397742, 3858816.
38. Bai X, Wei G, Sinha A, Esko JD. Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I. J Biol Chem 1999, 274(19):13017-13024. 10.1074/jbc.274.19.13017, 10224052.
39. Dathe M, Schumann M, Wieprecht T, Winkler A, Beyermann M, Krause E, Matsuzaki K, Murase O, Bienert M. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996, 35(38):12612-12622. 10.1021/bi960835f, 8823199.
40. Yanagishita M, Hascall VC. Proteoglycans synthesized by rat ovarian granulosa cells in culture. Isolation, fractionation, and characterization of proteoglycans associated with the cell layer. J Biol Chem 1984, 259(16):10260-10269.
41. Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 1976, 15(18):3932-3942. 10.1021/bi00663a005, 9127.
42. Uhlin-Hansen L, Yanagishita M. Differential effect of brefeldin A on the biosynthesis of heparan sulfate and chondroitin/dermatan sulfate proteoglycans in rat ovarian granulosa cells in culture. J Biol Chem 1993, 268(23):17370-17376.
43. Esko JD, Elgavish A, Prasthofer T, Taylor WH, Weinke JL. Sulfate transport-deficient mutants of Chinese hamster ovary cells. Sulfation of glycosaminoglycans dependent on cysteine. J Biol Chem 1986, 261(33):15725-15733.
44. Mader JS, Smyth D, Marshall J, Hoskin DW. Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am J Pathol 2006, 169(5):1753-1766. 10.2353/ajpath.2006.051229, 1780222, 17071598.
45. Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal O. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res 2004, 61(2):101-109. 10.1016/j.antiviral.2003.09.001, 14670583.
46. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 1993, 53(13):3052-3057.
47. Soballe PW, Maloy WL, Myrga ML, Jacob LS, Herlyn M. Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer 1995, 60(2):280-284. 10.1002/ijc.2910600225, 7829229.
48. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I. Bovine lactoferrin and Lactoferricin inhibit tumor metastasis in mice. Adv Exp Med Biol 1998, 443:285-291.
49. Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005, 4(4):612-624. 10.1158/1535-7163.MCT-04-0077, 15827335.
50. Yang N, Lejon T, Rekdal O. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci 2003, 9(5):300-311. 10.1002/psc.457, 12803496.
51. Yang N, Stensen W, Svendsen JS, Rekdal O. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res 2002, 60(4):187-197. 10.1034/j.1399-3011.2002.21008.x, 12366526.
52. Sok M, Sentjurc M, Schara M. Membrane fluidity characteristics of human lung cancer. Cancer Lett 1999, 139(2):215-220. 10.1016/S0304-3835(99)00044-0, 10395181.
53. Chaudhary J, Munshi M. Scanning electron microscopic analysis of breast aspirates. Cytopathology 1995, 6(3):162-167. 10.1111/j.1365-2303.1995.tb00469.x, 7669927.
54. Domagala W, Koss LG. Surface configuration of human tumor cells obtained by fine needle aspiration biopsy. Scan Electron Microsc 1980, (3):101-108.
55. Risso A, Braidot E, Sordano MC, Vianello A, Macri F, Skerlavaj B, Zanetti M, Gennaro R, Bernardi P. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 2002, 22(6):1926-1935. 10.1128/MCB.22.6.1926-1935.2002, 135593, 11865069.
56. Matsuzaki K, Sugishita K, Fujii N, Miyajima K. Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2. Biochemistry 1995, 34(10):3423-3429. 10.1021/bi00010a034, 7533538.
57. Mason AJ, Marquette A, Bechinger B. Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys J 2007, 93(12):4289-4299. 10.1529/biophysj.107.116681, 2098721, 17766347.
58. Maher S, McClean S. Melittin exhibits necrotic cytotoxicity in gastrointestinal cells which is attenuated by cholesterol. Biochem Pharmacol 2008, 75(5):1104-1114. 10.1016/j.bcp.2007.10.029, 18068148.
59. Zhang L, Lawrence R, Frazier BA, Esko JD. CHO glycosylation mutants: proteoglycans. Methods Enzymol 2006, 416:205-221. 10.1016/S0076-6879(06)16013-9, 17113868.
60. Mackinnon WB, Dyne M, Hancock R, Grant AJ, Russell P, Mountford CE. Malignancy-related characteristics of wild type and drug-resistant Chinese hamster ovary cells. Pathology 1993, 25(3):268-276. 10.3109/00313029309066588, 7903445.
61. Belting M, Borsig L, Fuster MM, Brown JR, Persson L, Fransson LA, Esko JD. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci USA 2002, 99(1):371-376. 10.1073/pnas.012346499, 117567, 11752393.
62. Rees SG, Hughes W, Embery G. Interaction of glucuronic acid and iduronic acid-rich glycosaminoglycans and their modified forms with hydroxyapatite. Biomaterials 2002, 23(2):481-489. 10.1016/S0142-9612(01)00130-2, 11761169.
63. Zelezetsky I, Pacor S, Pag U, Papo N, Shai Y, Sahl HG, Tossi A. Controlled alteration of the shape and conformational stability of alpha-helical cell-lytic peptides: effect on mode of action and cell specificity. Biochem J 2005, 390(Pt 1):177-188. 1184573, 15836439.
64. Dennison SR, Wallace J, Harris F, Phoenix DA. Amphiphilic alpha-helical antimicrobial peptides and their structure/function relationships. Protein Pept Lett 2005, 12(1):31-39. 10.2174/0929866053406084, 15638801.
65. Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res 2004, 64(2):119-126.
66. Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt RJ. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys 1995, 323(2):279-287. 10.1006/abbi.1995.9963, 7487089.
67. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 1998, 20(2):156-167. 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R, 9631661.
68. Stenlund P, Lindberg MJ, Tibell LA. Structural requirements for high-affinity heparin binding: alanine scanning analysis of charged residues in the C-terminal domain of human extracellular superoxide dismutase. Biochemistry 2002, 41(9):3168-3175. 10.1021/bi011454r, 11863456.
69. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002, 22(5):2703-2710.